Skip Navigation


NDT Advance Access originally published online on November 26, 2008
Nephrology Dialysis Transplantation 2009 24(2):348-354; doi:10.1093/ndt/gfn653
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/2/348    most recent
gfn653v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Locatelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Locatelli, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)

Francesco Locatelli1, Adrian Covic2, Kai-Uwe Eckardt3, Andrzej Wiecek4, Raymond Vanholder5 and on behalf of the ERA-EDTA ERBP Advisory Board

1 Department of Nephrology, Dialysis and Renal Transplantation, ‘A. Manzoni’ Hospital, Lecco, Italy 2 Department of Nephrology, Dialysis and Transplantation, C. I. Parhon University Hospital, University of Medicine Gr. T. Popa, Iasi, Romania 3 Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Nuremberg, Germany 4 Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Katowice, Francuska, Poland 5 Nephrology Section, University Hospital, Ghent, Belgium

Correspondence and offprint requests to: Francesco Locatelli, Department of Nephrology, Dialysis and Renal Transplantation, ‘Alessandro Manzoni’ Hospital, Via Dell’ Eremo 9/11, 23900 Lecco, Italy. Tel: +39-0341-489850; Fax: +39-0341-489860; E-mail: nefrologia@ospedale.lecco.it

Keywords: anaemia; erythropoiesis stimulating agents; biosimilars; guidelines; pure red cell aplasia

The first 150 words of the full text of this article appear below.



   Introduction
 
Over the last few years, much has been done to develop guidelines on the basis of the strongest possible evidence because this allows an accurate description of the quality and/or degree of uncertainty of the recommendations and provides physicians with a valuable tool for judicious decisions. However, creating and updating evidence-based guidelines is extremely costly, and so the nephrological community has been trying to build up a single set of international guidelines under the aegis of Kidney Disease Improving Global Outcomes (KDIGO) [1]. As part of this unifying effort, the working group responsible for the 2006 update of the National Kidney Foundation–Kidney Disease Outcome Quality Initiative (NKF-KDOQI) guidelines on anaemia management in patients with chronic kidney disease (CKD) [2], and the 2007 update on haemoglobin (Hb) targets [3], included members from Europe, Middle East, Mexico and Canada. However, this international effort may not be . . . [Full Text of this Article]



   NKF-KDOQI update, 2006
 


   Haemoglobin target: NKF-KDOQI update, September 2007
 


   Kidney Disease Improving Global Outcomes (KDIGO)
 


   The position of ERBP
 
Haemoglobin target
Anaemia evaluation
Targets for iron therapy
New ESAs
Epoetin delta
Continuous erythropoiesis receptor activator (CERA)
Biosimilars
Pure red cell aplasia


   Safety concerns in CKD patients with cancer
 


   Appendix: summary of recommendations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
F. Locatelli and H. Becker
Update on Anemia Management in Nephrology, Including Current Guidelines on the Use of Erythropoiesis-Stimulating Agents and Implications of the Introduction of "Biosimilars"
Oncologist, September 1, 2009; 14(suppl_1): 16 - 21.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Locatelli and P. Gascon
Is Nephrology More at Ease Than Oncology with Erythropoiesis-Stimulating Agents? Treatment Guidelines and an Update on Benefits and Risks
Oncologist, September 1, 2009; 14(suppl_1): 57 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
I. C. Macdougall
Anaemia ERBP Position statement
Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2288 - 2288.
[Full Text] [PDF]

Home page
 NDT PlusHome page
R. Vanholder, D. Abramowicz, J. B. Cannata-Andia, V. Cocchi, P. Cochat, A. Covic, K.-U. Eckardt, D. Fouque, O. Heimburger, S. Jenkins, et al.
The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP)
NDT Plus, June 1, 2009; 2(3): 213 - 221.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Covic
Reply
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1699 - 1700.
[Full Text] [PDF]